Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
GAIN THERAPEUTICS, INC.
ANNUAL REPORT FORM 10-K
TABLE OF CONTENTS
| · | ||
|---|---|---|
| | | Page |
| Cautionary Note Regarding Forward Looking Statements | 3 | |
| | | |
| Part I | | |
| Item 1. | Business | 5 |
| | | |
| Item 1A. | Risk Factors | 28 |
| | | |
| Item 1B. | Unresolved Staff Comments | 69 |
| | | |
| Item 1C. | Cybersecurity | 69 |
| | | |
| Item 2. | Properties | 70 |
| | | |
| Item 3. | Legal Proceedings | 70 |
| | | |
| Item 4. | Mine Safety Disclosures | 70 |
| | | |
| Part II | | |
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 70 |
| | | |
| Item 6. | Selected Financial Data | 71 |
| | | |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 71 |
| | | |
| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk | 82 |
| | | |
| Item 8. | Financial Statements and Supplementary Data | 83 |
| | | |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 117 |
| | | |
| Item 9A. | Controls and Procedures | 117 |
| | | |
| Item 9B. | Other information | 118 |
| | | |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 118 |
| | | |
| Part III | | |
| Item 10. | Directors, Executive Officers and Corporate Governance | 119 |
| | | |
| Item 11. | Executive Compensation | 127 |
| | | |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 136 |
| | | |
| Item 13. | Certain Relationships and Related Transactions and Director Independence | 137 |
| | | |
| Item 14. | Principal Accountant Fees and Services | 139 |
| | | |
| Part IV | | |
| Item 15. | Exhibits and Financial Statement Schedules | 140 |
| | | |
Unless the context suggests otherwise, references in this Annual Report on Form 10-K, or the Annual Report, to “Gain,” the “Company,” “we,” “us,” and “our” refer to Gain Therapeutics, Inc. and, where appropriate, its wholly owned subsidiaries.
Magellan™ is our trademark. All other brand names and service marks, trademarks and other trade names appearing in this Annual Report are the property of their respective owners.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.